Skip to Content

Addex Therapeutics Ltd ADR ADXN

Morningstar Rating
$8.79 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ADXN is trading at a 331% premium.
Price
$8.71
Fair Value
$41.89
Uncertainty
Extreme
1-Star Price
$363.55
5-Star Price
$5.40
Economic Moat
Dfcv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADXN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$8.79
Day Range
$8.368.79
52-Week Range
$5.0027.90
Bid/Ask
$7.52 / $8.94
Market Cap
$9.39 Mil
Volume/Avg
6,499 / 20,542

Key Statistics

Price/Earnings (Normalized)
Price/Sales
3.03
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
23

Valuation

Metric
ADXN
Price/Earnings (Normalized)
Price/Book Value
6.72
Price/Sales
3.03
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ADXN
Quick Ratio
1.39
Current Ratio
1.46
Interest Coverage
−490.52
Quick Ratio
ADXN

Profitability

Metric
ADXN
Return on Assets (Normalized)
−149.29%
Return on Equity (Normalized)
−261.29%
Return on Invested Capital (Normalized)
−243.84%
Return on Assets
ADXN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRTbvmflwcdjGfq$586.1 Bil
VRTX
Vertex Pharmaceuticals IncWynnlcyqVzzyq$113.7 Bil
REGN
Regeneron Pharmaceuticals IncXcbcyscNmqpt$108.2 Bil
MRNA
Moderna IncKsrwyndnSdypf$50.9 Bil
ARGX
argenx SE ADRLzvdpqxcGvhkz$22.0 Bil
BNTX
BioNTech SE ADRBbcthkmdZcsy$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncHwjdwqqpyTktcv$18.9 Bil
BMRN
Biomarin Pharmaceutical IncFljkvjsbsChvnv$14.6 Bil
INCY
Incyte CorpLkywxhxsPgfhjw$12.8 Bil
RPRX
Royalty Pharma PLC Class AWypygntnkZgwbjvw$12.3 Bil

Sponsor Center